Replies to post #244957 on Biotech Values

[DewDiligence]

TAK presents phase-2b TAK-279 data in psoriasis:

https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279

TAK-279 is a TYK2 inhibitor, the same class as BMY’s Sotyktu (#msg-169914579).

TAK bought TAK-279 from (private) Nimbus Therapeutics a few months ago for $4B in up-front cash + $2B in contingent payments (https://www.takeda.com/newsroom/newsreleases/2022/takeda-to-acquire-late-stage-potential-best-in-class-oral-allosteric-tyk2-inhibitor--ndi-034858-from-nimbus-therapeutics ), so we knew the TAK-279 data were going to be good.